Finch Therapeutics Plans $30M Ferring Sale to Wind Down

Finch Therapeutics Group is winding down through a chapter 11 plan built around a $30 million cash sale to Ferring Pharmaceuticals — the same company a jury found liable for willfully infringing Finch's fecal microbiota transplant patents and that now owes the estate a $29.5 million federal court judgment. The debtors' combined disclosure statement and plan, filed July 6, 2026, folds the sale directly into the plan structure, with the Ferring purchase agreement covering the company's remaining intellectual property, its microbial strain library, and the rights tied to the patent litigation itself.

Finch filed for chapter 11 protection on March 22, 2026 in the U.S. Bankruptcy Court for the District of Delaware, listing roughly $3.5 million in cash and no debtor-in-possession financing. The case has moved from a marketing process that produced no stalking horse bidder, through a multi-session auction that ran from June 15 to June 24, to the current plan-and-disclosure-statement stage, with a combined confirmation hearing scheduled for September 1, 2026.

Research Finch Therapeutics Group, Inc. with ElevenFlo

Ask the docket what happened, who is involved, and what comes next.

View case record

Finch Therapeutics Group, Inc.

What has changed in Finch Therapeutics Group, Inc. since this article was published?

Nasdaq Delisting, Lease Default, and Path to chapter 11

Finch's first-day declaration from CEO Matthew Blischak traces the filing to a company that had never generated positive cash flow and lost its last credible path to raising capital. The microbiome-therapeutics developer discontinued its CP101 Phase III trial for recurrent C. difficile infection in January 2023 after slower-than-expected enrollment. In its March 2023 results release, Finch said that decision led to a workforce reduction of about 95% and that it had fully repaid its $16.2 million Hercules Capital facility. Nasdaq notified the company of delisting on February 16, 2024, and the stock has traded on OTC Markets since.

The immediate trigger was real estate. Finch stopped paying rent on its Charlestown, Massachusetts office in October 2025, and landlord Hood Park, LLC delivered a notice of default on November 10, 2025 for a lease carrying roughly $51.6 million in total fixed rent over its ten-year term and an initial annual base rent near $4.5 million. With the office space unused, the debtors moved on the petition date to reject the lease and pursue a court-supervised sale of their remaining assets — chiefly their intellectual property portfolio and the proceeds of a patent lawsuit against Ferring Pharmaceuticals — rather than continue operating.

Ferring Patent Verdict and the $29.5 Million Judgment

Finch and the University of Minnesota sued Ferring Pharmaceuticals and its Rebiotix Inc. unit in patent litigation that began in December 2021, when Ferring sought a declaratory judgment that Finch's fecal-transplant patents were invalid. A jury returned a verdict for Finch and UMN on August 9, 2024, finding that Ferring willfully infringed three patents, and the district court entered judgment of $25,815,061 on August 15, 2024. Post-trial motions delayed collection for nearly two years; the combined plan reports that the district court issued a final judgment on July 2, 2026 in favor of the debtors and UMN totaling $29,505,816.72, plus ongoing royalties and post-judgment interest. Finch's first-day declaration told the court it lacked the liquidity to keep funding the litigation through further appeals — one of the reasons the debtors opted to monetize the patents and the judgment through a sale rather than litigate to conclusion.

Sale Process and the $30 Million Ferring Purchase

The court approved bidding procedures for a sale of substantially all assets on April 22, 2026, with Rock Creek Advisors running the process as sales agent. The debtors did not land a stalking horse bidder; a deadline originally set for May 7, 2026 was extended to May 28, 2026 without a signed agreement. Marketing proceeded without stalking-horse protections, and the auction opened June 15, 2026, continued on June 18, 22, and 23, and concluded June 24, 2026. The originally scheduled June 17 sale hearing was cancelled as the process continued, and the amended hearing agenda that week also reflected a limited objection and reservation of rights from Kirkland & Ellis over contract-assumption and cure-amount notices, along with two limited objections — one sealed, one redacted — from OpenBiome Foundation to the proposed sale order.

Ferring emerged as the winning bidder for $30 million in cash, covering Finch's intellectual property, its microbial strain library, and the rights tied to the district court judgment and the underlying patent litigation against Ferring itself. Rather than close under section 363 on a standalone basis, the debtors chose to implement the transaction through their chapter 11 plan; the Ferring asset purchase agreement includes a fallback allowing Ferring to seek a standalone sale order if the plan is not confirmed by September 1, 2026.

Rock Creek's retention as financial advisor and sales agent set a $30,000 monthly sales-agent fee plus a contingent success fee of 4% of transaction value up to $15 million and 8% above that threshold, credited against monthly fees already paid and payable only from cash the estates actually receive.

Combined Plan and Claims Treatment

The debtors' combined disclosure statement and plan proposes to pay other secured claims, other priority claims, general unsecured claims, and intercompany claims in full. Finch equity interests are impaired and would share pro rata in cash remaining after claims, reserves, and wind-down costs are covered; intercompany interests are impaired with no recovery.

The plan would release Released Parties from claims tied to the debtors, the chapter 11 cases, or the restructuring transactions, while third-party releases apply only to non-voting creditors who submit opt-in election forms and to Class 5 equity holders who opt in on their ballots. It also proposes exculpation for Exculpated Parties' conduct between the petition date and the effective date — excluding actual fraud, willful misconduct, and gross negligence — backed by a permanent injunction against collecting released claims.

A plan administrator would reconcile claims, wind down the estates, and make distributions after confirmation. The debtors are also seeking to push back their exclusivity periods; their motion to extend exclusivity asks the court for roughly 90 more days — to October 19, 2026 to file a plan and December 17, 2026 to solicit votes — against original deadlines of July 20 and September 18, 2026, respectively. The court has set July 24, 2026 for a hearing on interim approval of the disclosure statement and solicitation procedures, alongside the exclusivity motion. The plan itself schedules the combined final disclosure-statement and confirmation hearing for September 1, 2026 at 10:00 a.m. Eastern, with an August 25, 2026 deadline for confirmation objections, subject to adjournment.

Key Timeline

Frequently Asked Questions

Who is the claims agent for Finch Therapeutics?

Omni Agent Solutions serves as the claims and noticing agent, retained among the debtors' first-day motions to handle claims administration and case noticing for the jointly administered proceedings.

Did Finch need debtor-in-possession financing?

No. The debtors funded the case from approximately $3.5 million in cash on hand at the petition date rather than seeking a DIP facility.

What happens to Finch's patent litigation against Ferring?

The debtors' plan channels the intellectual property and litigation rights tied to the district court judgment against Ferring into the same $30 million sale in which Ferring is the buyer, rather than treating the litigation as a separate recovery source.

Was there a stalking horse bidder for Finch's assets?

No. The debtors extended their stalking-horse deadline to May 28, 2026 without securing a signed agreement, and proceeded to a multi-session auction without stalking-horse bid protections.

For other biotech 363 sales and liquidating plans, see ElevenFlo's coverage of Lipella Pharmaceuticals' IP sale after a Nasdaq delisting, Sangamo Therapeutics' debt-free sale process, and Timber Pharmaceuticals' credit-bid sale and liquidating plan.